<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30530" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Trastuzumab</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Greenblatt</surname>
            <given-names>Karl</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Khaddour</surname>
            <given-names>Karam</given-names>
          </name>
          <aff>Rosalind Franklin University of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Karl Greenblatt declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Karam Khaddour declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>22</day>
          <month>6</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30530.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Trastuzumab is an FDA-approved antineoplastic biologic that targets HER2-positive breast and gastric cancer. This activity outlines trastuzumab's various&#x000a0;indications and off-label uses, including&#x000a0;its combination with anthracycline or taxane-based chemotherapy for breast cancer, as monotherapy or&#x000a0;in combination with paclitaxel for metastatic breast cancer, and in combination with cisplatin-based chemotherapy for gastric cancer. This discussion also includes the mechanism of action, administration methods, significant adverse effects, FDA-issued box warnings, toxicity profile, and monitoring requirements of trastuzumab. Understanding these elements is crucial for tailoring&#x000a0;therapy&#x000a0;to meet patient needs, optimizing dosing regimens, and minimizing adverse reactions.</p>
        <p>The&#x000a0;activity also highlights the critical role of the interprofessional healthcare team in effectively managing conditions that trastuzumab is prescribed to treat. Knowledge of trastuzumab's pharmacology enables providers to make decisions that improve patient outcomes. Healthcare professionals are provided with the necessary scientific foundation to enhance patient care through targeted and personalized treatment strategies.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Evaluate the mechanism of action of trastuzumab.</p></list-item><list-item><p>Identify the possible therapy combinations that include trastuzumab.</p></list-item><list-item><p>Identify&#x000a0;the potential adverse effects associated with trastuzumab therapy.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from trastuzumab therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30530&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30530">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30530.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Trastuzumab is a biologic antineoplastic agent that&#x000a0;was FDA-approved in 1998,&#x000a0;making it&#x000a0;one of the first available &#x0201c;targeted&#x0201d; chemotherapies.&#x000a0;Trastuzumab deruxtecan is a trastuzumab conjugate that releases its cytotoxic components after binding and entering HER2-expressing cells, effectively&#x000a0;treating HER2-positive gastric,&#x000a0;lung, colorectal, and&#x000a0;metastatic breast cancer.<xref ref-type="bibr" rid="article-30530.r1">[1]</xref>&#x000a0;</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p><bold>HER2-positive gastric cancer:</bold>&#x000a0;Trastuzumab is&#x000a0;administered&#x000a0;with cisplatin-based chemotherapy, a combination that modestly improves survival (median 13.8 months vs. 11.1 months).<xref ref-type="bibr" rid="article-30530.r2">[2]</xref><xref ref-type="bibr" rid="article-30530.r3">[3]</xref>&#x000a0;Trastuzumab deruxtecan is a&#x000a0;newer antibody-drug conjugate&#x000a0;associated with positive outcomes, particularly&#x000a0;during later-line therapy.&#x000a0;As a first-line treatment, the combination of pembrolizumab, trastuzumab, and chemotherapy&#x000a0;demonstrated a remarkable response rate, prompting its&#x000a0;quick FDA approval.<xref ref-type="bibr" rid="article-30530.r3">[3]</xref><xref ref-type="bibr" rid="article-30530.r2">[2]</xref></p>
        <p><bold>Non-small cell lung cancer:</bold>&#x000a0;Trastuzumab deruxtecan&#x000a0;is approved for HER2-mutant (unresectable or metastatic) NSCLC in adults who have previously received systemic therapy.<xref ref-type="bibr" rid="article-30530.r4">[4]</xref>&#x000a0;Per the American Society of Clinical Oncology (ASCO) 2024 guidelines&#x000a0;regarding Stage IV Non&#x02013;Small Cell Lung Cancer with driver alterations, clinicians may offer treatment with trastuzumab deruxtecan.<xref ref-type="bibr" rid="article-30530.r5">[5]</xref></p>
        <p><bold>HER2-positive breast cancer:&#x000a0;</bold>Trastuzumab is FDA-approved&#x000a0;in combination with anthracycline or taxane-based chemotherapy. The maximum recommended duration of adjuvant treatment with trastuzumab is 12 months.</p>
        <p><bold>Metastatic HER2-positive breast cancer:</bold>&#x000a0;Trastuzumab is approved as monotherapy or&#x000a0;in combination with paclitaxel.<xref ref-type="bibr" rid="article-30530.r6">[6]</xref>&#x000a0;In June 2020, the FDA approved a combination of pertuzumab, trastuzumab, and hyaluronidase (subcutaneous) for patients with HER2-positive early-stage and metastatic breast cancer.<xref ref-type="bibr" rid="article-30530.r7">[7]</xref>&#x000a0;Trastuzumab has also been&#x000a0;administered in combination with lapatinib,&#x000a0;anastrozole,&#x000a0;cyclophosphamide, pertuzumab, and several other agents to treat metastatic breast cancer.<xref ref-type="bibr" rid="article-30530.r8">[8]</xref><xref ref-type="bibr" rid="article-30530.r9">[9]</xref><xref ref-type="bibr" rid="article-30530.r10">[10]</xref><xref ref-type="bibr" rid="article-30530.r11">[11]</xref>&#x000a0;According to the American Society of Clinical Oncology (ASCO), HER2-targeted therapy is recommended for patients with HER2-positive advanced breast cancer, except for&#x000a0;patients with congestive heart failure or a significantly reduced left ventricular ejection fraction, which should be evaluated individually.&#x000a0;As&#x000a0;a first-line treatment, ASCO recommends trastuzumab, pertuzumab, and taxanes. If pertuzumab is not available, clinicians may offer a combination of chemotherapy and trastuzumab.<xref ref-type="bibr" rid="article-30530.r6">[6]</xref><xref ref-type="bibr" rid="article-30530.r11">[11]</xref></p>
        <p><bold>Colorectal cancer: </bold>The FDA approved trastuzumab and tucatinib&#x000a0;as treatments for colorectal cancer in January 2023.<xref ref-type="bibr" rid="article-30530.r12">[12]</xref>&#x000a0;This combination is approved&#x000a0;specifically for HER2-positive,&#x000a0;chemotherapy-refractory,&#x000a0;<italic toggle="yes">RAS</italic>&#x000a0;wild-type unresectable, or metastatic colorectal cancer.<xref ref-type="bibr" rid="article-30530.r12">[12]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p><bold>Endometrial cancer:</bold>&#x000a0;Trastuzumab is&#x000a0;used off-label to treat HER2-positive serous endometrial cancer.<xref ref-type="bibr" rid="article-30530.r13">[13]</xref>&#x000a0;In 25% to 30% of serous&#x000a0;endometrial carcinomas, HER2 protein overexpression&#x000a0;or gene amplification is observed,&#x000a0;suggesting&#x000a0;trastuzumab as a potentially effective component of targeted therapy.<xref ref-type="bibr" rid="article-30530.r14">[14]</xref></p>
        <p><bold>HER2-positive (IHC 3+) unresectable or metastatic solid tumors:</bold> Trastuzumab deruxtecan is administered to&#x000a0;adult patients with unresectable or metastatic HER2-positive (IHC 3+/immunohistochemistry 3+) solid tumors who have received prior treatment and have no sufficient alternative treatment options.<xref ref-type="bibr" rid="article-30530.r15">[15]</xref></p>
      </sec>
      <sec id="article-30530.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Trastuzumab is a monoclonal antibody against human epidermal growth factor receptor 2 (HER2)&#x000a0;that binds to an extracellular domain of this receptor and inhibits&#x000a0;its homodimerization, preventing HER2-mediated signaling.&#x000a0;Trastuzumab is also thought to facilitate antibody-dependent cellular cytotoxicity, leading to the death of cells that express HER2.<xref ref-type="bibr" rid="article-30530.r16">[16]</xref>&#x000a0;Antibody-drug conjugates (ADCs) are pharmacological agents that deliver cytotoxic payloads to cells expressing a target protein. Trastuzumab deruxtecan (T-DXd) is a third-generation ADC comprising a humanized monoclonal anti-HER2 antibody (trastuzumab) and a cytotoxic topoisomerase I inhibitor (DXd)&#x000a0;linked together by a cleavable tetrapeptide linker. T-DXd&#x000a0;has a characteristically&#x000a0;high drug-to-antibody ratio of 8:1. In comparison, trastuzumab emtansine (T-DM1) is a second-generation ADC that combines trastuzumab with the cytotoxic agent emtansine.<xref ref-type="bibr" rid="article-30530.r17">[17]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;Trastuzumab administered with hyaluronidase demonstrates enhanced subcutaneous absorption. Trastuzumab's peak and trough plasma concentrations at steady state are typically observed between weeks 16 and 32.</p>
        <p><bold>Distribution:</bold>&#x000a0;Trastuzumab's mean apparent volume of distribution is ~44 mL/kg,&#x000a0;similar to its serum volume.&#x000a0;Whether trastuzumab traverses the blood-brain barrier or penetrates the cerebrospinal fluid remains unclear.</p>
        <p><bold>Metabolism:</bold> Following HER2 binding, trastuzumab is metabolized intracellularly into peptides and amino acids. Trastuzumab is thought to be eliminated by IgG clearance through the reticuloendothelial system.<xref ref-type="bibr" rid="article-30530.r18">[18]</xref></p>
        <p><bold>Elimination:</bold> Trastuzumab exhibits nonlinear kinetics (dose-dependent).&#x000a0;Renal excretion of trastuzumab is minimal.&#x000a0;The estimated elimination half-life of trastuzumab is 28 days, which may increase with tumor burden.<xref ref-type="bibr" rid="article-30530.r19">[19]</xref><xref ref-type="bibr" rid="article-30530.r20">[20]</xref>&#x000a0;Individual variation in drug clearance rates is considerable; increased body weight and&#x000a0;a reduced serum albumin level have been associated with increased trastuzumab clearance.<xref ref-type="bibr" rid="article-30530.r21">[21]</xref></p>
      </sec>
      <sec id="article-30530.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Trastuzumab is available in 50 mg (single-dose) vials and 420 mg (multidose) vials. Biosimilars of trastuzumab include trastuzumab-dkst, trastuzumab-strf, trastuzumab-pkrb, trastuzumab-dttb, trastuzumab-qyyp, and trastuzumab-anns. Trastuzumab and hyaluronidase is a&#x000a0;combination formulation&#x000a0;administered subcutaneously to enhance its absorption and dispersion, offering a convenient alternative to intravenous administration.<xref ref-type="bibr" rid="article-30530.r22">[22]</xref></p>
        <p>
<bold>Adult Dosing</bold>
</p>
        <p>Trastuzumab is administered as an intravenous infusion over 30 to 90 minutes.&#x000a0;This drug should not be administered as a bolus&#x000a0;or concurrently with D5W. Per the National Institute for Occupational Safety and Health (NIOSH) guidelines, double gloves, a gown, and closed-system transfer devices are required during administration, as trastuzumab is a potentially hazardous drug. The recommended maintenance dose is 2 mg/kg infused weekly or 6 mg/kg once every&#x000a0;3 weeks. Initial loading doses of up to 8 mg/kg may be administered.</p>
        <p>Institutional protocols and package insert information should be consulted for toxicity-related dose adjustments&#x000a0;before administration. Trastuzumab dosing for approved indications include:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>HER2-overexpressing breast cancer:
<list list-type="bullet"><list-item><p>As adjuvant treatment in combination with paclitaxel or docetaxel:&#x000a0;4 mg/kg IV for a single dose in week 1, followed by 2 mg/kg IV weekly for weeks 2 through 12, then 6 mg/kg IV every&#x000a0;3 weeks for weeks 13 through 52; paclitaxel and docetaxel are administered for the first 12 weeks.</p></list-item><list-item><p>In combination with carboplatin or docetaxel:&#x000a0;4 mg/kg IV for a single dose in week 1, followed by 2 mg/kg IV weekly for weeks 2 through 18, then 6 mg/kg IV every&#x000a0;3 weeks for weeks 19 through 52; paclitaxel and docetaxel are administered for the first 18&#x000a0;weeks.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>HER2-overexpressing metastatic breast cancer:
<list list-type="bullet"><list-item><p>In combination with paclitaxel: 4 mg/kg IV for a single dose in week 1, then 2 mg/kg IV every week starting in week 2.</p></list-item><list-item><p>In combination with pertuzumab: 8 mg/kg IV for a single dose on day&#x000a0;1 of the first 21-day cycle, then 6 mg/kg for the second 21-day cycle.</p></list-item><list-item><p>As monotherapy for recurrent disease: 4 mg/kg IV for a single dose&#x000a0;in the first week, then 2 mg/kg starting in week 2.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>HER2-overexpressing metastatic stomach cancer: 8 mg/kg IV for a single dose on day 1 of the first 21-day cycle, then&#x000a0;6&#x000a0;mg/kg IV for a single dose on day 1 of the second 21-day cycle.</p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold> No dosage adjustments are provided on the product labeling.</p>
        <p><bold>Renal impairment:</bold>&#x000a0;No dosage adjustments are provided on the&#x000a0;product&#x000a0;labeling.</p>
        <p><bold>Pregnancy considerations:</bold> The pharmacovigilance program closely monitors trastuzumab's effects during pregnancy. If administered during pregnancy or if the patient becomes pregnant within&#x000a0;7 months post-treatment, healthcare providers should monitor for signs of potential fetal harm, including oligohydramnios and pulmonary and skeletal abnormalities.&#x000a0;The patient's pregnancy status should be confirmed before treatment is offered, and women&#x000a0;who may become pregnant should use contraception during trastuzumab treatment and for&#x000a0;7 months afterward to prevent unintended fetal harm.<xref ref-type="bibr" rid="article-30530.r23">[23]</xref></p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;Information&#x000a0;regarding the effect of&#x000a0;trastuzumab during breastfeeding is limited. Trastuzumab is a high molecular weight protein, so&#x000a0;the amount excreted into breast milk is likely minimal.&#x000a0;Any ingested protein is likely partially degraded in the infant's gastrointestinal tract,&#x000a0;so the risk of&#x000a0;absorption is&#x000a0;minimal. However, caution should be exercised when considering trastuzumab during breastfeeding (particularly&#x000a0;if the nursing infant is newborn or preterm) until more data become available. The manufacturer recommends discontinuing breastfeeding during trastuzumab therapy and for 7&#x000a0;months after the last dose.<xref ref-type="bibr" rid="article-30530.r24">[24]</xref></p>
        <p><bold>Pediatric patients:</bold>&#x000a0;The safety and efficacy of trastuzumab have not been established in pediatric patients.</p>
        <p><bold>Older patients:</bold>&#x000a0;Older adults&#x000a0;have&#x000a0;demonstrated an increased risk of cardiac dysfunction compared to younger patients when using trastuzumab; caution is advised before prescribing to this patient population.</p>
      </sec>
      <sec id="article-30530.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Trastuzumab is known to cause cardiotoxicity,&#x000a0;which typically manifests as a&#x000a0;reduced left ventricular ejection fraction (LVEF). The exact pathogenesis of this event is unknown but&#x000a0;is thought to involve&#x000a0;reduced clearance of reactive oxygen species in cardiac myocytes.<xref ref-type="bibr" rid="article-30530.r25">[25]</xref>&#x000a0;In the U.S., trastuzumab carries an FDA-boxed warning regarding subclinical and clinical cardiac failure. According to the product label, a&#x000a0;reduction in LVEF &#x02265;10% has been observed in up to 22% of patients, although some studies have reported an incidence as high as 44%.<xref ref-type="bibr" rid="article-30530.r26">[26]</xref>&#x000a0;Symptomatic congestive heart failure during treatment is less common, with an estimated incidence of 2% to 7%. The major risk factor for cardiotoxicity is concurrent treatment with anthracyclines; the risk of severe cardiotoxicity is&#x000a0;3 to&#x000a0;4 times higher in patients receiving trastuzumab and anthracyclines simultaneously.<xref ref-type="bibr" rid="article-30530.r27">[27]</xref>&#x000a0;Increased age, hypertension, coronary artery disease, and hyperlipidemia may also increase a patient's risk of cardiotoxicity. Clinically, most cases of trastuzumab-induced cardiotoxicity appear to be reversible&#x000a0;after discontinuing treatment.<xref ref-type="bibr" rid="article-30530.r28">[28]</xref><xref ref-type="bibr" rid="article-30530.r29">[29]</xref>&#x000a0;However, some patients demonstrate&#x000a0;echocardiographic evidence of persistent myocardial dysfunction.<xref ref-type="bibr" rid="article-30530.r30">[30]</xref></p>
        <p>Severe infusion reactions&#x000a0;are associated with&#x000a0;trastuzumab administration, including angioedema, anaphylaxis, interstitial pneumonitis, and acute respiratory distress syndrome. Trastuzumab also carries an FDA-boxed warning about these effects. Most severe&#x000a0;effects&#x000a0;occur within 24 hours of infusion. All patients should be monitored for significant dyspnea, hypotension, or signs of angioedema; trastuzumab should be discontinued if any of these effects are observed. Some patients can tolerate resumed infusion after pre-medication (eg, with acetaminophen and diphenhydramine).</p>
        <p>Rare cases of nephrotic syndrome have been reported in patients on trastuzumab therapy, with the greatest incidence in patients with metastatic gastric cancer.</p>
        <p>Other adverse effects commonly reported&#x000a0;during trastuzumab monotherapy include headache, chills, nausea/vomiting,&#x000a0;abdominal pain,&#x000a0;diarrhea,&#x000a0;cough,&#x000a0;back pain, rhinitis,&#x000a0;pharyngitis,&#x000a0;weakness, and fatigue.</p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Trastuzumab should not be administered with belimumab due to an increased risk of neutropenia and infection.</p>
        <p>Patients receiving anthracyclines (eg, doxorubicin) following trastuzumab discontinuation&#x000a0;are at an increased risk for cardiotoxicity. To minimize cardiotoxicity risk, anthracyclines should be&#x000a0;deferred for 7 months following trastuzumab cessation.<xref ref-type="bibr" rid="article-30530.r31">[31]</xref>&#x000a0;Close cardiac monitoring is necessary if anthracyclines must be administered.</p>
      </sec>
      <sec id="article-30530.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Box Warnings</bold>
</p>
        <p><bold>Cardiomyopathy:</bold> Trastuzumab is known to cause cardiotoxicity,&#x000a0;which typically manifests as a&#x000a0;reduced left ventricular ejection fraction (LVEF). The exact pathogenesis of this event is unknown but&#x000a0;is thought to involve&#x000a0;reduced clearance of reactive oxygen species in cardiac myocytes.<xref ref-type="bibr" rid="article-30530.r25">[25]</xref>&#x000a0;In the U.S., trastuzumab carries an FDA-boxed warning regarding subclinical and clinical cardiac failure. According to the product label, a&#x000a0;reduction in LVEF &#x02265;10% has been observed in up to 22% of patients, although some studies have reported an incidence as high as 44%.<xref ref-type="bibr" rid="article-30530.r26">[26]</xref>&#x000a0;Symptomatic congestive heart failure during treatment is less common, with an estimated incidence of 2% to 7%. The major risk factor for cardiotoxicity is concurrent treatment with anthracyclines; the risk of severe cardiotoxicity is&#x000a0;3 to&#x000a0;4 times higher in patients receiving trastuzumab and anthracyclines simultaneously.<xref ref-type="bibr" rid="article-30530.r27">[27]</xref>&#x000a0;Increased age, hypertension, coronary artery disease, and hyperlipidemia may also increase a patient's risk of cardiotoxicity. Clinically, most cases of trastuzumab-induced cardiotoxicity appear to be reversible&#x000a0;after discontinuing treatment.<xref ref-type="bibr" rid="article-30530.r28">[28]</xref><xref ref-type="bibr" rid="article-30530.r29">[29]</xref>&#x000a0;However, some patients demonstrate&#x000a0;echocardiographic evidence of persistent myocardial dysfunction.<xref ref-type="bibr" rid="article-30530.r30">[30]</xref>&#x000a0;Due to the risk of cardiotoxicity, trastuzumab should be used with extreme caution in patients with&#x000a0;a history of structural heart disease.</p>
        <p><bold><bold>Pulmonary toxicity</bold>:&#x000a0;</bold>Trastuzumab is associated with severe and potentially fatal pulmonary toxicity. Interstitial pneumonitis, non-cardiogenic pulmonary edema, pleural effusions, acute respiratory distress syndrome, and pulmonary fibrosis have also been reported. These adverse events can occur as a sequela of infusion reactions. Patients with&#x000a0;a history of lung disease or malignancy appear to experience more severe toxicity.</p>
        <p><bold>Embroyofetal toxicity:&#x000a0;</bold>Trastuzumab use during pregnancy is associated with oligohydramnios, which can lead to fatal pulmonary hypoplasia, skeletal abnormalities, and neonatal death.&#x000a0;Before initiating trastuzumab therapy, the pregnancy status of&#x000a0;women&#x000a0;who&#x000a0;may become pregnant must be confirmed.&#x000a0;Clinicians should advise effective contraception during treatment and for&#x000a0;7 months following the last dose.</p>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p><bold>Pregnancy:</bold> Trastuzumab is&#x000a0;thought to be a human teratogen. Fetal exposure is associated with oligohydramnios, leading to pulmonary hypoplasia and death. Patients&#x000a0;who may become pregnant should use at least one form of contraception&#x000a0;during&#x000a0;trastuzumab therapy.&#x000a0;Whether trastuzumab is secreted in human breast milk or not is unclear.</p>
        <p><bold>Infusion reactions:</bold> Severe infusion reactions have been observed&#x000a0;during&#x000a0;trastuzumab administration. These may include angioedema, anaphylaxis, interstitial pneumonitis, and acute respiratory distress syndrome. Trastuzumab also carries an FDA-boxed warning about these reactions. Severe&#x000a0;effects typically&#x000a0;occur within 24 hours of infusion. All patients should be monitored for significant dyspnea, hypotension, or signs of angioedema; trastuzumab should be discontinued if any of these effects are observed. Some patients&#x000a0;can tolerate resuming therapy after pre-medication (eg, with acetaminophen and diphenhydramine).<xref ref-type="bibr" rid="article-30530.r32">[32]</xref></p>
        <p><bold>Neutropenia:</bold> Trastuzumab may exacerbate chemotherapy-induced neutropenia. Grade 3 and 4 neutropenia and febrile neutropenia have been observed&#x000a0;more commonly&#x000a0;in patients receiving trastuzumab in combination with myelosuppressive chemotherapy.</p>
        <p><bold>Biosimilars</bold>: Multiple biosimilar trastuzumab&#x000a0;formulations are available; the specific product label should be verified before administering trastuzumab.<xref ref-type="bibr" rid="article-30530.r33">[33]</xref></p>
      </sec>
      <sec id="article-30530.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Echocardiography is recommended before initiating trastuzumab treatment. Cardiac risk factors such as hypertension and smoking should also be noted if present. The role of echocardiography in&#x000a0;screening asymptomatic patients during treatment is uncertain. One guideline-recommended alternative is to obtain an&#x000a0;echocardiogram at baseline, one after treatment, and one 6 to 12 months following treatment.<xref ref-type="bibr" rid="article-30530.r34">[34]</xref>&#x000a0;In clinical practice, asymptomatic patients receiving anthracyclines (eg, doxorubicin or baseline cardiac risk factors) often undergo echocardiography every 2 to 3 months. Patients with metastatic disease receiving indefinite therapy may also undergo routine echocardiography.<xref ref-type="bibr" rid="article-30530.r35">[35]</xref>&#x000a0;Symptomatic patients should&#x000a0;undergo immediate echocardiography, cardiac biomarker testing, and referral to cardiology. Trastuzumab should be discontinued if the LVEF is less than 50% and is&#x000a0;reduced by more than 10% from baseline or if the LVEF is reduced by more than 16% from baseline. In&#x000a0;some cases, trastuzumab may be restarted if the LVEF is restored.</p>
        <p>When trastuzumab is combined with paclitaxel, an increased serum concentration of trastuzumab has been observed. Serum paclitaxel concentrations may also be decreased&#x000a0;during trastuzumab therapy.<xref ref-type="bibr" rid="article-30530.r36">[36]</xref>&#x000a0;The mechanism and clinical significance of these interactions are unknown.</p>
        <p>Trastuzumab may increase the risk of neutropenia, infections, and anemia when added to cytotoxic chemotherapy.</p>
      </sec>
      <sec id="article-30530.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>The major toxicity concerns regarding trastuzumab include cardiotoxicity, embryo-fetal toxicity, and pulmonary toxicity. There is no antidote for trastuzumab toxicity.&#x000a0;For an accidental overdose, immediate supportive care should be provided, and consultations with oncology and toxicology specialists should be obtained.</p>
      </sec>
      <sec id="article-30530.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Trastuzumab is a biologic agent primarily used to treat HER2-positive breast cancer and may be used as&#x000a0;adjuvant therapy for localized disease or as first-line treatment for metastatic disease. The&#x000a0;availability of trastuzumab has significantly increased survival associated with HER2-positive breast cancer; notably, trastuzumab also carries considerable historical importance as one of the first &#x0201c;targeted&#x0201d; chemotherapeutic agents developed.&#x000a0;Trastuzumab is typically given in combination with one or more cytotoxic agents, most commonly anthracyclines (eg, doxorubicin) and taxanes (eg, paclitaxel). Trastuzumab has also demonstrated efficacy in the treatment of HER2-positive metastatic gastric cancer. The most significant adverse event associated with trastuzumab is cardiotoxicity; this is usually mild and reversible with discontinuation, but it may progress to irreversible, clinically significant cardiac failure.</p>
        <p>The risk of cardiotoxicity is&#x000a0;greatest in patients receiving concomitant anthracycline therapy. All patients should receive a baseline echocardiogram before initiating treatment and must be monitored closely for the development of palpitations, dyspnea, chest pain, and peripheral edema.&#x000a0;Some patients may benefit from a more frequent echocardiographic assessment. Immediate discontinuation of trastuzumab is warranted for a patient with a reduced LVEF. The interprofessional healthcare team, including clinicians (particularly oncology specialists), nurses, and pharmacists, must also be aware of the potential for severe infusion reactions, especially following the initial dose. Trastuzumab likely has teratogenic effects; it should be avoided in patients who are pregnant, and patients&#x000a0;who may become pregnant must use contraception during treatment. A cardiology consultation is recommended for patients with trastuzumab-induced cardiotoxicity. Pulmonology consultation may be required for interstitial lung disease.&#x000a0;An interprofessional team approach and communication among clinicians (MDs, DOs, NPs, PAs), pharmacists, and nurses is crucial for optimizing patient outcomes with trastuzumab.</p>
      </sec>
      <sec id="article-30530.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30530&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30530">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30530/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30530">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-30530.s11">
        <title>References</title>
        <ref id="article-30530.r1">
          <label>1</label>
          <element-citation publication-type="book">
            <chapter-title>Trastuzumab</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2024</year>
            <month>1</month>
            <day>30</day>
            <pub-id pub-id-type="pmid">31643875</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30530.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bang</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Van Cutsem</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Feyereislova</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sawaki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lordick</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ohtsu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Omuro</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Satoh</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Aprile</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kulikov</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lehle</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>R&#x000fc;schoff</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>YK</given-names>
              </name>
              <collab>ToGA Trial Investigators</collab>
            </person-group>
            <article-title>Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.</article-title>
            <source>Lancet</source>
            <year>2010</year>
            <month>Aug</month>
            <day>28</day>
            <volume>376</volume>
            <issue>9742</issue>
            <fpage>687</fpage>
            <page-range>687-97</page-range>
            <pub-id pub-id-type="pmid">20728210</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30530.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kawakami</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yamazaki</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Recent Progress in Treatment for HER2-Positive Advanced Gastric Cancer.</article-title>
            <source>Cancers (Basel)</source>
            <year>2024</year>
            <month>Apr</month>
            <day>30</day>
            <volume>16</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">38730700</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30530.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Waliany</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Neal</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Engel-Nitz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Le</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nagasaka</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>HER2-Mutant Advanced and/or Metastatic Non-Small-Cell Lung Cancer: A US Electronic Health Records Database Analysis of Clinical Characteristics, Treatment Practice Patterns, and Outcomes.</article-title>
            <source>Clin Lung Cancer</source>
            <year>2024</year>
            <month>Jun</month>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>319</fpage>
            <page-range>319-328.e1</page-range>
            <pub-id pub-id-type="pmid">38403548</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30530.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Owen</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Ismaila</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Freeman-Daily</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Roof</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Velazquez</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Leighl</surname>
                <given-names>NB</given-names>
              </name>
            </person-group>
            <article-title>Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.1.</article-title>
            <source>J Clin Oncol</source>
            <year>2024</year>
            <month>May</month>
            <day>30</day>
            <fpage>JCO2400762</fpage>
            <pub-id pub-id-type="pmid">38815183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30530.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al Sukhun</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Temin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Barrios</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Antone</surname>
                <given-names>NZ</given-names>
              </name>
              <name>
                <surname>Guerra</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Chavez-MacGregor</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chopra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Danso</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Gomez</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Homian</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Kandil</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kithaka</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Koczwara</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Moy</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nakigudde</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Petracci</surname>
                <given-names>FE</given-names>
              </name>
              <name>
                <surname>Rugo</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>El Saghir</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Arun</surname>
                <given-names>BK</given-names>
              </name>
            </person-group>
            <article-title>Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline.</article-title>
            <source>JCO Glob Oncol</source>
            <year>2024</year>
            <month>Jan</month>
            <volume>10</volume>
            <fpage>e2300285</fpage>
            <pub-id pub-id-type="pmid">38206277</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30530.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gao</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Osgood</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Gong</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bloomquist</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Qiu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rahman</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Chiu</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Ricks</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Rizvi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Abukhdeir</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Seidman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ghosh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Philip</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pierce</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Bhatnagar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kluetz</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Pazdur</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Beaver</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Amiri-Kordestani</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer.</article-title>
            <source>Clin Cancer Res</source>
            <year>2021</year>
            <month>Apr</month>
            <day>15</day>
            <volume>27</volume>
            <issue>8</issue>
            <fpage>2126</fpage>
            <page-range>2126-2129</page-range>
            <pub-id pub-id-type="pmid">33188141</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30530.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gianni</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pienkowski</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Im</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Roman</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tseng</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Lluch</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Staroslawska</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>de la Haba-Rodriguez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Im</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Pedrini</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Poirier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Morandi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Semiglazov</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Srimuninnimit</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bianchi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Szado</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ratnayake</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Valagussa</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-32</page-range>
            <pub-id pub-id-type="pmid">22153890</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30530.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Azambuja</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Piccart-Gebhart</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Di Cosimo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Swaby</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Untch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jackisch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Boyle</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Barrios</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Perez</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Azim</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Kuemmel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Vuylsteke</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Gorbunova</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Eniu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dreosti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tavartkiladze</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gelber</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Eidtmann</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Baselga</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.</article-title>
            <source>Lancet Oncol</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>15</volume>
            <issue>10</issue>
            <fpage>1137</fpage>
            <page-range>1137-46</page-range>
            <pub-id pub-id-type="pmid">25130998</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30530.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaufman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mackey</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Clemens</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Bapsy</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Vaid</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wardley</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tjulandin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jahn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lehle</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Feyereislova</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>R&#x000e9;vil</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.</article-title>
            <source>J Clin Oncol</source>
            <year>2009</year>
            <month>Nov</month>
            <day>20</day>
            <volume>27</volume>
            <issue>33</issue>
            <fpage>5529</fpage>
            <page-range>5529-37</page-range>
            <pub-id pub-id-type="pmid">19786670</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30530.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Swain</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Ewer</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Viale</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Delaloge</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ferrero</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Verrill</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Colomer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vieira</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Werner</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Douthwaite</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bradley</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Waldron-Lynch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kiermaier</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eng-Wong</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dang</surname>
                <given-names>C</given-names>
              </name>
              <collab>BERENICE Study Group</collab>
            </person-group>
            <article-title>Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study.</article-title>
            <source>Ann Oncol</source>
            <year>2018</year>
            <month>Mar</month>
            <day>01</day>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>646</fpage>
            <page-range>646-653</page-range>
            <pub-id pub-id-type="pmid">29253081</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30530.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Casak</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Horiba</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lemery</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Bi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Auth</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fesenko</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kluetz</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Pazdur</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fashoyin-Aje</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal Cancer.</article-title>
            <source>Clin Cancer Res</source>
            <year>2023</year>
            <month>Nov</month>
            <day>01</day>
            <volume>29</volume>
            <issue>21</issue>
            <fpage>4326</fpage>
            <page-range>4326-4330</page-range>
            <pub-id pub-id-type="pmid">37318379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30530.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chui</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Da Cruz Paula</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>da Silva</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Momeni-Boroujeni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reis-Filho</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Makker</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ellenson</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Weigelt</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Decreased HER2 expression in endometrial cancer following anti-HER2 therapy.</article-title>
            <source>J Pathol</source>
            <year>2024</year>
            <month>Feb</month>
            <volume>262</volume>
            <issue>2</issue>
            <fpage>129</fpage>
            <page-range>129-136</page-range>
            <pub-id pub-id-type="pmid">38013631</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30530.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buza</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>HER2 Testing in Endometrial Serous Carcinoma: Time for Standardized Pathology Practice to Meet the Clinical Demand.</article-title>
            <source>Arch Pathol Lab Med</source>
            <year>2021</year>
            <month>Jun</month>
            <day>01</day>
            <volume>145</volume>
            <issue>6</issue>
            <fpage>687</fpage>
            <page-range>687-691</page-range>
            <pub-id pub-id-type="pmid">32649220</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30530.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meric-Bernstam</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Makker</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Oaknin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>DY</given-names>
              </name>
              <name>
                <surname>Banerjee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez-Mart&#x000ed;n</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>&#x00141;ugowska</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Manso</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Manzano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Melichar</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Siena</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stroyakovskiy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fielding</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Puvvada</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shire</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JY</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.</article-title>
            <source>J Clin Oncol</source>
            <year>2024</year>
            <month>Jan</month>
            <day>01</day>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>47</fpage>
            <page-range>47-58</page-range>
            <pub-id pub-id-type="pmid">37870536</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30530.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Namboodiri</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Pandey</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Differential inhibition of trastuzumab- and cetuximab-induced cytotoxicity of cancer cells by immunoglobulin G1 expressing different GM allotypes.</article-title>
            <source>Clin Exp Immunol</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>166</volume>
            <issue>3</issue>
            <fpage>361</fpage>
            <page-range>361-5</page-range>
            <pub-id pub-id-type="pmid">22059994</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30530.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mosele</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Deluche</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lusque</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Le Bescond</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Filleron</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pradat</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ducoulombier</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pistilli</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bachelot</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Viret</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Signolle</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Alfaro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>DTN</given-names>
              </name>
              <name>
                <surname>Garberis</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Talbot</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Christodoulidis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vakalopoulou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Droin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Stourm</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kakegawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lacroix</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Saulnier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Job</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Deloger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jimenez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mahier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Baris</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Laplante</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kannouche</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Marty</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lacroix-Triki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Di&#x000e9;ras</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Andr&#x000e9;</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial.</article-title>
            <source>Nat Med</source>
            <year>2023</year>
            <month>Aug</month>
            <volume>29</volume>
            <issue>8</issue>
            <fpage>2110</fpage>
            <page-range>2110-2120</page-range>
            <pub-id pub-id-type="pmid">37488289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30530.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boekhout</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Beijnen</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Schellens</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Trastuzumab.</article-title>
            <source>Oncologist</source>
            <year>2011</year>
            <volume>16</volume>
            <issue>6</issue>
            <fpage>800</fpage>
            <page-range>800-10</page-range>
            <pub-id pub-id-type="pmid">21632460</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30530.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bruno</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Washington</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Lieberman</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Banken</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer.</article-title>
            <source>Cancer Chemother Pharmacol</source>
            <year>2005</year>
            <month>Oct</month>
            <volume>56</volume>
            <issue>4</issue>
            <fpage>361</fpage>
            <page-range>361-9</page-range>
            <pub-id pub-id-type="pmid">15868146</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30530.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bernadou</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Campone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Merlin</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Gouilleux-Gruart</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bachelot</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lokiec</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rezai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Arnedos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Di&#x000e9;ras</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Jimenez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Paintaud</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ternant</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2016</year>
            <month>May</month>
            <volume>81</volume>
            <issue>5</issue>
            <fpage>941</fpage>
            <page-range>941-8</page-range>
            <pub-id pub-id-type="pmid">26714164</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30530.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cosson</surname>
                <given-names>VF</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>VW</given-names>
              </name>
              <name>
                <surname>Lehle</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lum</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title>Population pharmacokinetics and exposure-response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer.</article-title>
            <source>Cancer Chemother Pharmacol</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>73</volume>
            <issue>4</issue>
            <fpage>737</fpage>
            <page-range>737-47</page-range>
            <pub-id pub-id-type="pmid">24519752</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30530.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duco</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Murdock</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Reeves</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Trastuzumab/Hyaluronidase-oysk: A New Option for Patients With HER2-Positive Breast Cancer.</article-title>
            <source>Ann Pharmacother</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>54</volume>
            <issue>3</issue>
            <fpage>254</fpage>
            <page-range>254-261</page-range>
            <pub-id pub-id-type="pmid">31595774</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30530.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andrikopoulou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Apostolidou</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chatzinikolaou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bletsa</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zografos</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dimopoulos</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Zagouri</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Trastuzumab administration during pregnancy: an update.</article-title>
            <source>BMC Cancer</source>
            <year>2021</year>
            <month>Apr</month>
            <day>26</day>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>463</fpage>
            <pub-id pub-id-type="pmid">33902516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30530.r24">
          <label>24</label>
          <element-citation publication-type="book">
            <chapter-title>Trastuzumab</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>3</month>
            <day>18</day>
            <pub-id pub-id-type="pmid">29999639</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30530.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mohan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Endo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>ElZarrad</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Trastuzumab, but Not Pertuzumab, Dysregulates HER2 Signaling to Mediate Inhibition of Autophagy and Increase in Reactive Oxygen Species Production in Human Cardiomyocytes.</article-title>
            <source>Mol Cancer Ther</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>1321</fpage>
            <page-range>1321-31</page-range>
            <pub-id pub-id-type="pmid">27197303</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30530.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farolfi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Melegari</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Aquilina</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scarpi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ibrahim</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Maltoni</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sarti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cecconetto</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pietri</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ferrario</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fedeli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Faedi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nanni</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Frassineti</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Amadori</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rocca</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors.</article-title>
            <source>Heart</source>
            <year>2013</year>
            <month>May</month>
            <volume>99</volume>
            <issue>9</issue>
            <fpage>634</fpage>
            <page-range>634-9</page-range>
            <pub-id pub-id-type="pmid">23349345</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30530.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mantarro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bonifazi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>D'Amico</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Blandizzi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>La Vecchia</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Negri</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Moja</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer.</article-title>
            <source>Intern Emerg Med</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>123</fpage>
            <page-range>123-40</page-range>
            <pub-id pub-id-type="pmid">26712595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30530.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hamirani</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fanous</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kramer</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Salerno</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dillon</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Anthracycline- and trastuzumab-induced cardiotoxicity: a retrospective study.</article-title>
            <source>Med Oncol</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>33</volume>
            <issue>7</issue>
            <fpage>82</fpage>
            <pub-id pub-id-type="pmid">27334792</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30530.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Azambuja</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Procter</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>van Veldhuisen</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Agbor-Tarh</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Metzger-Filho</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Steinseifer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Untch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>IE</given-names>
              </name>
              <name>
                <surname>Gianni</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Baselga</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jackisch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cameron</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Leyland-Jones</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dowsett</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gelber</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Piccart-Gebhart</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Suter</surname>
                <given-names>TM</given-names>
              </name>
            </person-group>
            <article-title>Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).</article-title>
            <source>J Clin Oncol</source>
            <year>2014</year>
            <month>Jul</month>
            <day>10</day>
            <volume>32</volume>
            <issue>20</issue>
            <fpage>2159</fpage>
            <page-range>2159-65</page-range>
            <pub-id pub-id-type="pmid">24912899</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30530.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tan</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Bouras</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sawaya</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sebag</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Picard</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Passeri</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kuter</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Scherrer-Crosbie</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Time Trends of Left Ventricular Ejection Fraction and&#x000a0;Myocardial Deformation Indices in a Cohort of&#x000a0;Women with Breast Cancer Treated with Anthracyclines, Taxanes, and Trastuzumab.</article-title>
            <source>J Am Soc Echocardiogr</source>
            <year>2015</year>
            <month>May</month>
            <volume>28</volume>
            <issue>5</issue>
            <fpage>509</fpage>
            <page-range>509-14</page-range>
            <pub-id pub-id-type="pmid">25772019</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30530.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Quartino</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kirschbrown</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Mangat</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wada</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Garg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Lum</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin<sup>&#x000ae;</sup>), a HER2-targeted monoclonal antibody, in patients with a variety of solid tumors.</article-title>
            <source>Cancer Chemother Pharmacol</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>83</volume>
            <issue>2</issue>
            <fpage>329</fpage>
            <page-range>329-340</page-range>
            <pub-id pub-id-type="pmid">30467591</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30530.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barroso</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Estevinho</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hespanhol</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Teixeira</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ramalho-Carvalho</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ara&#x000fa;jo</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Management of infusion-related reactions in cancer therapy: strategies and&#x000a0;challenges.</article-title>
            <source>ESMO Open</source>
            <year>2024</year>
            <month>Mar</month>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>102922</fpage>
            <pub-id pub-id-type="pmid">38452439</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30530.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodriguez</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mancuso</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lyman</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Cardoso</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Nahleh</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Vose</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Gralow</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Francisco</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sherwood</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>ASCO Policy Statement on Biosimilar and Interchangeable Products in Oncology.</article-title>
            <source>JCO Oncol Pract</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>19</volume>
            <issue>7</issue>
            <fpage>411</fpage>
            <page-range>411-419</page-range>
            <pub-id pub-id-type="pmid">37027797</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30530.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Plana</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Galderisi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Barac</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ewer</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Ky</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Scherrer-Crosbie</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ganame</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sebag</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Agler</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Badano</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Banchs</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cardinale</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Carver</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cerqueira</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>DeCara</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Edvardsen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Flamm</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Force</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Jerusalem</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Magalh&#x000e3;es</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marwick</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sanchez</surname>
                <given-names>LY</given-names>
              </name>
              <name>
                <surname>Sicari</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Villarraga</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Lancellotti</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.</article-title>
            <source>J Am Soc Echocardiogr</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>27</volume>
            <issue>9</issue>
            <fpage>911</fpage>
            <page-range>911-39</page-range>
            <pub-id pub-id-type="pmid">25172399</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30530.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davis</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Zelnak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eley</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Switchenko</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>McKibbin</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Clinical Utility of Routine Cardiac Monitoring in Breast Cancer Patients Receiving Trastuzumab.</article-title>
            <source>Ann Pharmacother</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>50</volume>
            <issue>9</issue>
            <fpage>712</fpage>
            <page-range>712-7</page-range>
            <pub-id pub-id-type="pmid">27307412</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30530.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Furtlehner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schueller</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jarisch</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ostermann</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Czejka</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Disposition of paclitaxel (Taxol) and its metabolites in patients with advanced breast cancer (ABC) when combined with trastuzumab (Hercpetin).</article-title>
            <source>Eur J Drug Metab Pharmacokinet</source>
            <year>2005</year>
            <season>Jul-Sep</season>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>145</fpage>
            <page-range>145-50</page-range>
            <pub-id pub-id-type="pmid">16250250</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
